Literature DB >> 17710673

Penetrance of the C28Y/C282Y genotype of the HFE gene.

Arne Asberg1, Kristian Hveem, Kjell Kannelønning, Wenche Øiestad Irgens.   

Abstract

OBJECTIVE: Hereditary hemochromatosis is a common genetic disease caused by accumulation of iron in the body. Most cases are homozygous for the C282Y mutation in the HFE gene, but only a minority of homozygotes will ever suffer from clinical hemochromatosis. Estimates of the penetrance of the C282Y/C282Y genotype vary greatly. The purpose of this study was to estimate the penetrance using a stringent definition, i.e. liver cirrhosis.
MATERIAL AND METHODS: The results from previous phenotypic population screening for hereditary hemochromatosis were combined with findings in hospital databases in order to estimate the number of C282Y homozygotes with and without liver cirrhosis in a Norwegian county. The penetrance of the C282Y/C282Y genotype was estimated as the fraction of C282Y homozygotes with liver cirrhosis. We also calculated the expected number of male C282Y homozygotes with liver cirrhosis using figures for age-specific accumulated risk.
RESULTS: The prevalence of liver cirrhosis in male homozygotes is between 3.4% and 5.0%. This figure is compatible with an accumulated risk of liver cirrhosis that increases from 0.2% at 35 years to about 10% at 65 years of age. In female homozygotes, the prevalence of liver cirrhosis is 0.3%.
CONCLUSIONS: A small but significant number of Norwegian male C282Y homozygotes will contract liver cirrhosis if their hemochromatosis is not diagnosed and treated in time. The penetrance is much lower in women than in men.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17710673     DOI: 10.1080/00365520701245488

Source DB:  PubMed          Journal:  Scand J Gastroenterol        ISSN: 0036-5521            Impact factor:   2.423


  9 in total

1.  Clinical guidelines: HFE hemochromatosis-screening, diagnosis and management.

Authors:  James C Barton; Paul C Adams
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2010-09       Impact factor: 46.802

2.  Down-regulation of hepcidin in porphyria cutanea tarda.

Authors:  Richard S Ajioka; John D Phillips; Robert B Weiss; Diane M Dunn; Maria W Smit; Sean C Proll; Michael G Katze; James P Kushner
Journal:  Blood       Date:  2008-09-22       Impact factor: 22.113

3.  Genetic tests: clinical validity and clinical utility.

Authors:  Wylie Burke
Journal:  Curr Protoc Hum Genet       Date:  2014-04-24

4.  Profound morphological changes in the erythrocytes and fibrin networks of patients with hemochromatosis or with hyperferritinemia, and their normalization by iron chelators and other agents.

Authors:  Etheresia Pretorius; Janette Bester; Natasha Vermeulen; Boguslaw Lipinski; George S Gericke; Douglas B Kell
Journal:  PLoS One       Date:  2014-01-09       Impact factor: 3.240

5.  Return of individual research results from genome-wide association studies: experience of the Electronic Medical Records and Genomics (eMERGE) Network.

Authors:  Stephanie M Fullerton; Wendy A Wolf; Kyle B Brothers; Ellen Wright Clayton; Dana C Crawford; Joshua C Denny; Philip Greenland; Barbara A Koenig; Kathleen A Leppig; Noralane M Lindor; Catherine A McCarty; Amy L McGuire; Eugenia R McPeek Hinz; Daniel B Mirel; Erin M Ramos; Marylyn D Ritchie; Maureen E Smith; Carol J Waudby; Wylie Burke; Gail P Jarvik
Journal:  Genet Med       Date:  2012-02-23       Impact factor: 8.822

Review 6.  Clinical penetrance in hereditary hemochromatosis: estimates of the cumulative incidence of severe liver disease among HFE C282Y homozygotes.

Authors:  Scott D Grosse; Lyle C Gurrin; Nadine A Bertalli; Katrina J Allen
Journal:  Genet Med       Date:  2017-08-03       Impact factor: 8.822

7.  Penetrance of Hemochromatosis in HFE Genotypes Resulting in p.Cys282Tyr and p.[Cys282Tyr];[His63Asp] in the eMERGE Network.

Authors:  Carlos J Gallego; Amber Burt; Agnes S Sundaresan; Zi Ye; Christopher Shaw; David R Crosslin; Paul K Crane; S Malia Fullerton; Kris Hansen; David Carrell; Helena Kuivaniemi; Kimberly Derr; Mariza de Andrade; Catherine A McCarty; Terrie E Kitchner; Brittany K Ragon; Sarah C Stallings; Gabriella Papa; Joseph Bochenek; Maureen E Smith; Sharon A Aufox; Jennifer A Pacheco; Vaibhav Patel; Elisha M Friesema; Angelika Ludtke Erwin; Omri Gottesman; Glenn S Gerhard; Marylyn Ritchie; Arno G Motulsky; Iftikhar J Kullo; Eric B Larson; Gerard Tromp; Murray H Brilliant; Erwin Bottinger; Joshua C Denny; Dan M Roden; Marc S Williams; Gail P Jarvik
Journal:  Am J Hum Genet       Date:  2015-09-10       Impact factor: 11.025

8.  EMQN best practice guidelines for the molecular genetic diagnosis of hereditary hemochromatosis (HH).

Authors:  Graça Porto; Pierre Brissot; Dorine W Swinkels; Heinz Zoller; Outi Kamarainen; Simon Patton; Isabel Alonso; Michael Morris; Steve Keeney
Journal:  Eur J Hum Genet       Date:  2015-07-08       Impact factor: 4.246

9.  Clinical Penetrance of Hereditary Hemochromatosis-Related End-Organ Damage of C282Y Homozygosity, A Newfoundland Experience.

Authors:  Dennis R Lim; Gokul Vidyasankar; Chai Phua; Mark Borgaonkar
Journal:  Clin Transl Gastroenterol       Date:  2020-11       Impact factor: 4.396

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.